Transitioning psoriasis patients to adalimumab following a suboptimal response to etanercept, methotrexate, or phototherapy: efficacy and safety results from an open-label study

被引：0

作者：

Strober, B. ^{[1
]}

Poulin, Y. ^{[2
]}

Kerdel, F. ^{[3
]}

Langley, R. ^{[4
]}

Menter, A. ^{[5
]}

Papp, K. ^{[6
]}

Gu, Y. ^{[7
]}

Okun, M. ^{[7
]}

机构：

[1] NYU, Sch Med, New York, NY USA

[2] Ctr Dermatol Quebec Metropolitain, Quebec City, PQ, Canada

[3] Florida Acad Dermatol Ctr, Miami, FL USA

[4] Dalhousie Univ, Halifax, NS, Canada

[5] Baylor Psoriasis Res Inst, Dallas, TX USA

[6] Clin Res, Waterloo, ON, Canada

[7] Abbott Labs, Abbott Pk, IL 60064 USA

来源：

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

P021

引用

页码：9 / 9

页数：1